Price cap on 2 key cancer drugs increased by 50%

The regulator has also revised prices of anti-tetanus immunoglobulin and three key childhood vaccines to ensure their continued availability. The decision, for which a gazette notification has been issued, was taken at NPPA's 147th meeting on Thursday, where the authority invoked its extraordinary powers under Para 19 of the Drug Price Control Order (DPCO), 2013, to revise prices of formulations considered critical for public health.